

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representations to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



BBI LIFE SCIENCES CORPORATION
BBI 生命科學有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1035)

VOLUNTARY ANNOUNCEMENT

INVESTMENT IN A BIOTECH COMPANY

This announcement is made by BBI Life Sciences Corporation (the “**Company**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the recent business development of the Company.

Agreement

The board of directors of the Company (the “**Board**”) is pleased to announce that during the non-trading hours on 6 March 2017, Sangon Health Sci-Tech (Shanghai) Company Limited (生工健康科技(上海)有限公司) (“**Sangon Health**”), a VIE company of the Company (that was set up by the chairman of the Company : Mr Wang Qisong, as the sole shareholder, and through a series of control protocols with Sangon Biotech (Shanghai) Co., Ltd, a subsidiary of the Company, formed a VIE model company.), entered into an investment agreement (the “**Agreement**”) with the shareholders of Tianjin Hengjia Boitech Development Company Limited (天津亨佳生物科技發展有限公司) (“**Tianjin Hengjia**”). Pursuant to the Agreement, Sangon Health will obtain 34% equity interest of Tianjin Hengjia by investment, with an increase in the capital amount of RMB6 million.

General Information of Tianjin Hengjia

Tianjin Hengjia is principally engaged in the research and application of technologies and therapeutic methods related to “Autologous mutation peptides for treatment of cancer”. Genetic analysis technology is adopted in such methods in a way that analyzing the oncogene of pathological tissues of patients with malignant tumors, and finding out the mutation portion that can resist tumors, and based on these information, to synthesize tumor antigen peptide vaccine with specificity, and activate the immune system of patients, so as to finally achieve the purpose of specifically eliminating cancer cells. The completed clinic test results show that such technologies can increase effectively the number of specific immune cells of cancer patients, so as to control the tumors, improve the health condition of patients and extend patients’ life.

Reasons for and Benefit of Entering into the Agreement

How to accurately target and specifically ablate tumours and cancer cells has become an urgent problem to be solved in the academia and a hotspot in the bioscience industry since the advent of Precision Medicine and Cancer Moonshot. With our expertise in peptide synthesis and in development, the Company has been working closely with Tianjin Hengjia on the project "Clinical Research on Autologous Mutation Peptides for Treatment of Cancer (自體突變肽鏈治療癌症臨床研究)" since 2015, to provide excellent self-mutated peptide chain products for such clinical research projects and ensure the steady proceeding of the project. At present, such clinical research program has achieved exciting staged successes. The Company and Tianjin Hengjia are of a view that the investment in Tianjin Hengjia by the subsidiary of the Company promotes the establishment of a closer cooperative relationship between them, which ensures the smooth progress of the program of "Clinical Research on Autologous Mutation Peptides for Treatment of Cancer".

Investment in Tianjin Hengjia will generate opportunities on the basis of four major business segments of the Company, that is to conduct business in the field of clinical medicine, which can utilize fully the technology advantages of the Company in life science, as well as enhance the competitiveness of the Company in the future market.

As the applicable percentage ratios (as defined in Rule 14.07 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) in respect of the above-mentioned transaction are lower than 5%, under Chapter 14 of the **Listing Rules**, the above-mentioned transaction does not constitute a notifiable transaction of the Company, this announcement is made by the Company on a voluntary basis, for the purpose of informing the shareholders of the Company and potential investors about the latest business development of the Company.

By order of the Board
BBI Life Sciences Corporation
Wang Qisong
Chairman

Hong Kong, 6 March 2017

As at the date of this announcement, the Board comprises Mr. Wang Qisong, Ms. Wang Luojia and Ms. Wang Jin as executive directors; Mr. Hu Xubo as non-executive director; and Mr. Xia Lijun, Mr. Ho Kenneth Kai Chung and Mr. Liu Jianjun as independent non-executive directors.